STING agonists activate cGAS–STING signaling, inducing type-I interferon programs that re-prime mitochondrial apoptosis and enhance antigen presentation, particularly in TP53-mutant AML, where DNA-damage and kinase therapies often fail. The gene discussed is TP53; the disease is acute myeloid leukemia.